Endocannabinoid CB2 Receptor Neurons are neurons that express the CB2 cannabinoid receptor, a G protein-coupled receptor (GPCR) primarily associated with immune modulation and anti-inflammatory signaling. Unlike the widely expressed CB1 receptor, CB2 has limited expression in the CNS under normal conditions but is markedly upregulated in pathological states, particularly in microglia and neurons during neuroinflammation[1].
CB2-expressing neurons play crucial roles in modulating neuroinflammatory responses, regulating synaptic function, and providing neuroprotection in various neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, and multiple sclerosis[2].
| Property | Value |
|---|---|
| Receptor Type | CB2 (CNR2) |
| Gene Symbol | CNR2 |
| Family | Cannabinoid receptor (Class A GPCR) |
| Signaling Mechanism | Gi/o protein-coupled, inhibits adenylate cyclase, modulates MAPK pathways |
| Amino Acids | 360 (human) |
The CB2 receptor signals primarily through Gi/o proteins, producing several downstream effects:
CB2 expression in the CNS is highly regulated and context-dependent:
CB2-expressing neurons include subpopulations in:
In Alzheimer's disease, CB2 receptor expression is elevated in proximity to amyloid-beta plaques. Activation of CB2:
In Parkinson's disease, CB2 is upregulated in dopaminergic neurons of the substantia nigra pars reticulata and in activated microglia in the nigrostriatal pathway. CB2 agonism:
CB2-expressing neurons and microglia form a regulatory circuit:
Selective CB2 agonists have shown promise in preclinical models:
| Compound | Preclinical Effect | Reference |
|---|---|---|
| JWH133 | Reduced microglial activation, protected dopaminergic neurons in MPTP mouse model | [2:2] |
| GP1a | Inhibited neuroinflammation, reduced tau pathology in 3xTg-AD mice | [6] |
| LY2828360 | Attenuated LPS-induced neuroinflammation, reduced cytokine levels | [3:2] |
CB2-targeted therapies face challenges including:
Several CB2-targeting compounds have reached early clinical stages for neurodegenerative indications. Development focuses on:
Hanlon CD, Sharkey KA, Mitchell HA. Cannabinoid receptor signaling in the enteric nervous system and gastrointestinal motility. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2022. ↩︎ ↩︎
Galiazzo G, Panarello G, Schiera G, et al. Cannabinoids and neuroprotection in basal ganglia disorders. Journal of Molecular Neuroscience. 2018. ↩︎ ↩︎ ↩︎
Schneider E, Popiolek M, Krewson L, Romero-Sandoval EA. Cannabinoid receptor 2 signaling in neurodegenerative disease pathogenesis. Journal of Neurochemistry. 2021. ↩︎ ↩︎ ↩︎
Fernandez-Ruiz J, Gonzalez C, Hernandez ML, de Lago E, Ramos JA. Pathogenic relevance of the endocannabinoid system in brain disorders. The Endocannabinoid System. 2015. ↩︎
Cheng Y, Bai F, Liu M, Guo Q, Li Z. The endocannabinoid system and its therapeutic potential in neurodegenerative diseases. Acta Pharmacologica Sinica. 2014. ↩︎ ↩︎
Altman DA, Congreve E, Osornio AL, Jancovich ER, Gopinath JK. Cannabinoid CB2 receptor as a potential therapeutic target for neurodegenerative diseases. Expert Opinion on Therapeutic Targets. 2019. ↩︎ ↩︎